The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01630863 |
Recruitment Status : Unknown
Verified February 2015 by Min Sagong, Yeungnam University College of Medicine.
Recruitment status was: Recruiting
First Posted : June 28, 2012
Last Update Posted : February 16, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Central Serous Chorioretinopathy | Procedure: Photodynamic therapy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy |
Study Start Date : | June 2012 |
Actual Primary Completion Date : | October 2014 |
Estimated Study Completion Date : | March 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: 50% group
power of PDT is applied to the patients at 50% of the full energy based on TAP study.
|
Procedure: Photodynamic therapy
Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA. |
Experimental: 40% group
Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
|
Procedure: Photodynamic therapy
Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA. |
Experimental: 30% group
Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
|
Procedure: Photodynamic therapy
Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA. |
- Changes of best corrected visual acuity [ Time Frame: 6 month ]Changes of best corrected visual acuity at baseline and 1, 3, 6 month after PDT
- Change of central retinal thickness, success rate, recurrence rate, and complications [ Time Frame: 6 months ]Change of the central retinal thickness on optical coherence tomography (OCT)are compared at baseline at 1, 3, and 6 months after PDT. Additionally, success rate, recurrence rate, and complications between three groups are evaluated during 6 months.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA
- Presence of SRF and/or serous pigment epithelial detachment on optical coherence tomography (OCT)
- Presence of abnormal dilated choroidal vasculature in ICGA
- Patients with symptomatic CSC of at least 3 months duration
Exclusion Criteria:
- Patients who received any previous treatment, including PDT or focal thermal laser photocoagulation for CSC, or who had evidence of CNV, PCV, or other maculopathy on clinical examination, FA, or ICGA
- Patients receiving exogenous corticosteroid treatment
- Patients with systemic diseases such as Cushing's disease or renal diseases
- Pregnant patients

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01630863
Contact: Min Sagong | 82-53-620-4191 | msagong@ynu.ac.kr |
Korea, Republic of | |
Yeungnam University College of Medicine | Recruiting |
Daegu, Korea, Republic of | |
Contact: Min Sagong 82-53-620-4191 msagong@ynu.ac.kr | |
Principal Investigator: Min Sagong |
Responsible Party: | Min Sagong, Assistant Professor, Yeungnam University College of Medicine |
ClinicalTrials.gov Identifier: | NCT01630863 |
Other Study ID Numbers: |
YUH-12-007-D4 |
First Posted: | June 28, 2012 Key Record Dates |
Last Update Posted: | February 16, 2015 |
Last Verified: | February 2015 |
Central serous chorioretinopathy photodynamic therapy safe and effective dose |
Central Serous Chorioretinopathy Retinal Diseases Eye Diseases |